Description: This review summarizes recent evidence showing that continuous glucose monitoring (CGM) can meaningfully improve care for adults with type 2 diabetes. Across studies published from 2020 to 2025, CGM use was linked to better blood sugar control, including lower HbA1c, more time in target range, and improved self-management, in both insulin-treated and non-insulin-treated patients. Broader benefits are also highlighted, including possible reductions in mortality and health care use. However, access remains uneven, with disparities related to race and ethnicity, age, insurance coverage, and care setting. CGM is a high-value tool for type 2 diabetes management, but wider and more equitable implementation is needed.

Citation: Perini Villanueva, G., Solorzano, W. M., & Everett, E. (2026). Continuous Glucose Monitoring in Type 2 Diabetes: Clinical Outcomes, Disparities in Access, and Cost-effectiveness. Current diabetes reports, 26(1), 19. https://doi.org/10.1007/s11892-026-01631-8